ProNAi Therapeutics is a drug development company advancing targeted therapeutics with the potential to dramatically change the lives of patients with cancer. We are an ambitious oncology drug development company oriented towards registration and commercialization. We have a world-class management team with a proven track record of success in oncology drug development and we intend to build a broad and diverse pipeline of promising oncology assets against emerging targets on the leading edge of cancer biology.
Our portfolio includes PNT141, a potent, selective and orally bioavailable small molecule inhibitor of Cdc7. This kinase is a key regulator of both DNA replication and DNA damage response, making it a compelling emerging target for the potential treatment of a broad range of tumor types.